The authors found that Saroglitazar significantly reduced TG (baseline: 321.0 mg/dL to week-24: 129.0 mg/dL) and ALT (baseline: 89.0 IU/L to week-24: 21.0 IU/L) and improved fatty liver (evaluated by transient elastography (FibroScanTM)) in 39% (86/221) patients [18]. This evidence concerns the gene GPT and Hepatic steatosis.